Digital PCR (dPCR) is an established method for the fast and reliable identification of significant cancer-related mutations. For liquid biopsy analysis, dPCR assays are a precise, cost-effective, and rapid method for monitoring response and resistance to treatment by testing for relevant cancer-driver and therapy-resistant mutations.
The TaqMan dPCR Liquid Biopsy assays detect and quantify the most common cancer-related mutations (e.g., EGFR, BRAF, KRAS, PIK3CA, JAK2), as well as therapy-resistant mutations (e.g., EGFR T790M). They have been verified and are guaranteed* to perform on the QuantStudio 3D Digital PCR System and other dPCR and droplet digital PCR (ddPCR) instruments, including the Bio-Rad QX-100™ and QX-200™ systems.**
Poster: TaqMan dPCR Liquid Biopsy Assays targeting the TERT promoter region
The TERT promotor region has a high incidence of mutations in multiple cancer types, yet detection of these mutations is difficult due to the high GC content and repetitive elements in this region. In this poster, learn about how we successfully designed and optimized TaqMan dPCR Liquid Biopsy Assays for TERT C228T and TERT C250T mutations with detection to 0.1%.
Key features of the TaqMan Liquid Biopsy dPCR Assays
Order TaqMan dPCR Liquid Biopsy Assays
Additional liquid biopsy solutions
Targeted next-generation sequencing (NGS) assays
Rare mutation detection assays
Cell-free nucleic acid extraction
For Research Use Only. Not for use in diagnostic procedures.
* Terms and conditions apply. For complete details, go to www.thermofisher.com/taqmanguarantee.
** Bio-Rad and Bio-Rad QX100 and QX200 Droplet Digital PCR Systems are trademarks of Bio-Rad Laboratories, Inc., which is not affiliated with Thermo Fisher Scientific. These statements have not been reviewed or endorsed by Bio-Rad. TaqMan is a registered trademark of Roche Molecular Systems, Inc., used under license.